Literature DB >> 23948888

AβPP-selective BACE inhibitors (ASBI): novel class of therapeutic agents for alzheimer's disease.

Olivier Descamps1, Patricia Spilman, Qiang Zhang, Clare P Libeu, Karen Poksay, Olivia Gorostiza, Jesus Campagna, Barbara Jagodzinska, Dale E Bredesen, Varghese John.   

Abstract

A systematic approach was used to identify AβPP-selective BACE inhibitors (ASBI) and to evaluate their in vivo ability to modulate AβPP processing selectively. We identified a bioflavonoid nutritional supplement as a molecular lead that acts as an ASBI in cell models, and show that increasing brain levels of this bioflavonoid through a pro-drug approach leads to reduction of Aβ42 in an Alzheimer's disease mouse model. ASBIs represent a novel class of candidate therapeutic agents for Alzheimer's disease.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23948888      PMCID： PMC3971881          DOI： 10.3233/JAD-130578

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN： 1387-2877            Impact factor:   4.472


  48 in total

1.  Galangin induces autophagy through upregulation of p53 in HepG2 cells.

Authors:  Min Wen; Jun Wu; Hui Luo; Haitao Zhang
Journal:  Pharmacology       Date:  2012       Impact factor: 2.547

2.  Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity.

Authors:  R Yan; M J Bienkowski; M E Shuck; H Miao; M C Tory; A M Pauley; J R Brashier; N C Stratman; W R Mathews; A E Buhl; D B Carter; A G Tomasselli; L A Parodi; R L Heinrikson; M E Gurney
Journal:  Nature       Date:  1999-12-02       Impact factor: 49.962

3.  Purification and cloning of amyloid precursor protein beta-secretase from human brain.

Authors:  S Sinha; J P Anderson; R Barbour; G S Basi; R Caccavello; D Davis; M Doan; H F Dovey; N Frigon; J Hong; K Jacobson-Croak; N Jewett; P Keim; J Knops; I Lieberburg; M Power; H Tan; G Tatsuno; J Tung; D Schenk; P Seubert; S M Suomensaari; S Wang; D Walker; J Zhao; L McConlogue; V John
Journal:  Nature       Date:  1999-12-02       Impact factor: 49.962

Review 4.  The development of molecular clamps as drugs.

Authors:  Stephanie T Weiss; Neil R McIntyre; Mark L McLaughlin; David J Merkler
Journal:  Drug Discov Today       Date:  2006-09       Impact factor: 7.851

5.  Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP.

Authors:  J Lewis; D W Dickson; W L Lin; L Chisholm; A Corral; G Jones; S H Yen; N Sahara; L Skipper; D Yager; C Eckman; J Hardy; M Hutton; E McGowan
Journal:  Science       Date:  2001-08-24       Impact factor: 47.728

6.  Increased activity-regulating and neuroprotective efficacy of alpha-secretase-derived secreted amyloid precursor protein conferred by a C-terminal heparin-binding domain.

Authors:  K Furukawa; B L Sopher; R E Rydel; J G Begley; D G Pham; G M Martin; M Fox; M P Mattson
Journal:  J Neurochem       Date:  1996-11       Impact factor: 5.372

7.  Design, synthesis, and crystal structure of hydroxyethyl secondary amine-based peptidomimetic inhibitors of human beta-secretase.

Authors:  Michel C Maillard; Roy K Hom; Timothy E Benson; Joseph B Moon; Shumeye Mamo; Michael Bienkowski; Alfredo G Tomasselli; Danielle D Woods; D Bryan Prince; Donna J Paddock; Thomas L Emmons; John A Tucker; Michael S Dappen; Louis Brogley; Eugene D Thorsett; Nancy Jewett; Sukanto Sinha; Varghese John
Journal:  J Med Chem       Date:  2007-02-22       Impact factor: 7.446

8.  BACE1 (beta-secretase) transgenic and knockout mice: identification of neurochemical deficits and behavioral changes.

Authors:  Steve M Harrison; Alex J Harper; Julie Hawkins; Graham Duddy; Evelyn Grau; Pippa L Pugh; Panida H Winter; Claire S Shilliam; Zoë A Hughes; Lee A Dawson; M Isabel Gonzalez; Neil Upton; Menelas N Pangalos; Colin Dingwall
Journal:  Mol Cell Neurosci       Date:  2003-11       Impact factor: 4.314

Review 9.  The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.

Authors:  John Hardy; Dennis J Selkoe
Journal:  Science       Date:  2002-07-19       Impact factor: 47.728

Review 10.  Amyloid precursor protein trafficking, processing, and function.

Authors:  Gopal Thinakaran; Edward H Koo
Journal:  J Biol Chem       Date:  2008-07-23       Impact factor: 5.157
View more
  5 in total

1.  Gleevec shifts APP processing from a β-cleavage to a nonamyloidogenic cleavage.

Authors:  William J Netzer; Karima Bettayeb; Subhash C Sinha; Marc Flajolet; Paul Greengard; Victor Bustos
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-23       Impact factor: 11.205

2.  Development of Kinase Inactive PD173955 Analogues for Reducing Production of Aβ Peptides.

Authors:  Anjana Sinha; Katherina Gindinova; Emily Mui; William J Netzer; Subhash C Sinha
Journal:  ACS Med Chem Lett       Date:  2019-09-06       Impact factor: 4.345

3.  Galangin Suppresses Pro-Inflammatory Gene Expression in Polyinosinic-Polycytidylic Acid-Stimulated Microglial Cells.

Authors:  Min-Ji Choi; Jin-Sun Park; Jung-Eun Park; Han Su Kim; Hee-Sun Kim
Journal:  Biomol Ther (Seoul)       Date:  2017-11-01       Impact factor: 4.634

4.  Diplazium esculentum (Retz.) Sw. reduces BACE-1 activities and amyloid peptides accumulation in Drosophila models of Alzheimer's disease.

Authors:  Thanit Kunkeaw; Uthaiwan Suttisansanee; Dunyaporn Trachootham; Jirarat Karinchai; Boonrat Chantong; Saranyapin Potikanond; Woorawee Inthachat; Pornsiri Pitchakarn; Piya Temviriyanukul
Journal:  Sci Rep       Date:  2021-12-10       Impact factor: 4.379

Review 5.  Forest Biomass as a Promising Source of Bioactive Essential Oil and Phenolic Compounds for Alzheimer's Disease Therapy.

Authors:  Patrícia Moreira; Patrícia Matos; Artur Figueirinha; Lígia Salgueiro; Maria Teresa Batista; Pedro Costa Branco; Maria Teresa Cruz; Cláudia Fragão Pereira
Journal:  Int J Mol Sci       Date:  2022-08-08       Impact factor: 6.208
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.